Surfing the MASH Tsunami

Send us Fan Mail  Alina Allen and Ian Rowe lead the Surfers in considering biopathological shortcomings in fibrosis as a solitary endpoint. Their comments stem from Alina's presentation of the recent Mayo Clinic paper, "MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study." In this conversation, Alina summarizes the paper, after whi...

Send us Fan Mail Alina Allen and Stephen Harrison spearhead a discussion on how MRE results can provide a foundation for developing Subpart H Clinical Trial Endpoints from non-invasive testing data. Their comments stem from Alina's presentation of the recent Mayo Clinic paper, "MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study."...

Send us Fan Mail Alina Allen and Ian Rowe discuss how Liver Stiffness Measurements (LSM) can improve individual patient treatment in pre-cirrhotic and compensated cirrhotic patients. Their comments stem from Alina's presentation of the recent Mayo Clinic paper, "MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study." In this conversa...

Send us Fan Mail Alina Allen and Ian Rowe join the Surfers to discuss the recent Mayo Clinic paper, "MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study." In this conversation, Alina summarizes the paper, after which Stephen Harrison asks questions about availability of subgroup analysis.  This paper was recently published in the journa...

Send us Fan Mail Professors Alina Allen and Ian Rowe join the Surfers to discuss our ability to predict long-term outcomes using MR Elastography. The conversation flows around Mayo Clinic's recent Hepatology publication, "MRE for prediction of long term progression and outcome in chronic liver disease.   The ability to predict long-term outcomes using MR Elastography (MRE) and other non-...

Send us Fan Mail The entire panel enters a discussion around histopathology's shortcomings, ranging from the fact that the NAFLD Activity score does not correlate with liver function to inconsistencies in reading all elements of biopsy. This conversation revolves around the challenges posed by histopathology's flaws. Scott Friedman reminds us that NAFLD Activity scores do not correlate w...

Send us Fan Mail Stephen Harrison and Jörn Schattenberg join the conversation with questions that focus on patient treatment and drug development. The ultimate payoffs from Precision Medicine will come in better targeted, streamlined drug development along with improve ability to deliver the right drug to each patient. In this conversation, topics range from how cells signal distress to the value...

Send us Fan Mail Scott Friedman reprises key elements from his Paris NASH talk, focusing on Precision Medicine and some key factors that affect hepatic function that Precision Medicine must address. Scott Friedman describes Precision Medicine as "the right treatment or diagnostic for the right patient at the right time." In this precís of his Paris NASH talk, he discusses the factors tha...

Send us Fan Mail Scott Friedman, the "Father of Fibrosis", and Jörn Schattenberg join the Surfers to discuss Scott's recent Paris NASH and National Liver Congress talks on Precision Medicine, imaging and liver function. Scott Friedman's Paris NASH talk on Precision Medicine made a strong impression on Stephen and Jörn, along with our listeners. The conversation summary of that...

Send us Fan Mail Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. In this section, panel members speculate on the largest, most important conceptual changes that the new imaging approaches can drive in disease knowledge and research. This session begins with Lars discussi...

Send us Fan Mail Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. This conversation revolves around the implications of Lars's comment that we should track and analyze functioning hepatocyte cells as an excellent marker for liver function. This conversation starts wi...

Send us Fan Mail Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk. In this conversation, Lars and Stephen discuss the value of assessing the balance of fibrogenesis and fibrosis in healthy and unhealthy livers. Introducing our guest surfer, Stephen Harrison describes Lars...

Send us Fan Mail Antaros Medical's Chief Scientific Officer Lars Johansson joins Stephen Harrison, Louise Campbell, and Roger Green to reprise the key points of his recent Paris NASH talk and comment on several other topics. Lars Johansson's Paris NASH presentation, "Innovations in Imaging Assessment of Fibrosis"," introduced his audience to a dynamic, multidimensional vie...

Send us Fan Mail Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation answers the question "What Can Be Done Today?" in terms of screening and patient management without approved drugs. The paper "Clinical...

Send us Fan Mail Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation centers on two issues: driving behavior change and recognizing the scope of the need. For "Clinical Care Pathway for the Risk Stratification and...

Send us Fan Mail Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. This conversation centers on how the working group came to be and how they developed this pivotal paper. The path to publishing "Clinical Care Pathway for the Risk...

Send us Fan Mail Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway published in Gastroenterology. Last week, Gastroentrology published the article "Clinical Care Pathway for the Risk Stratification and Management of Patients with Nonalcoholic Fatty Liver Diseas...

Send us Fan Mail Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Roger uses a classical Marketing Research question to help the group sort out the relative impact potential of the ideas they have been discussing. This conversation starts with Roger Green using an old marketing research...

Send us Fan Mail Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Louise Campbell raises two very different points about the earlier conversation. Louise's first point has to do with steps taken to maintain compliance with clinical trials and whether researchers can analyze these in...

Send us Fan Mail Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Stephen Harrison starts by discussing some issues and insights around the use of FGF-21s and then "hijacks" the conversation to explore a standard practice in histopathology that he would like to change. This con...

Send us Fan Mail Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Stephen Harrison provides an image to suggest the enormity of the coming NASH pandemic and Mazen identifies his two biggest stories of summer. Mazen's "biggest things of summer" include Stephen's recent...

Send us Fan Mail Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer" with his own unique slant on recent events and publications. Mazen's take on the 'Biggest Stories of NASH Summer" integrates the content of papers, the journals in which they were published and the attention they received to form...

Send us Fan Mail Professor Manal Abdelmalek joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on NIH's recent decision to stand up and fund the Liver Cirrhosis Network. To Dr Abdelmalek, the NIH action signifies increased focus on the significant long-term consequences of Fatty Liver disease. She discusses a Q&A at a tal...

Send us Fan Mail Professor and epidemiologist Michelle Long joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on the recent paper on prevalence of NAFLD and NASH in an unselected middle-aged population. To Dr. Long, an epidemiologist, there has been very little high quality perspective research on NAFLD/NASH prevalence. She discu...

Send us Fan Mail Newly-appointed Professor Ian Rowe joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. He focuses on the recent FDA approval of the ELF test for prognosis of cirrhosis. To Professor Rowe, the ELF approval was the most important story of summer because it promises a brighter future for non-invasive tests and, eventually, decrea...